This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer: Five of the Best

And Disney's got a lot going for it. Disney's got not one, not two, but three successful hit machines in Pixar, Marvel and, starting next year, Star Wars. These are consistent winners that generate amazing returns that can then be amortized over theme parks, merchandise and, of course, sequels. Think about Disney as a consumer products company. Do you really believe that Procter (PG) or a Colgate (CL) can keep coming out with billion-dollar products every quarter as Disney's been doing? When you consider it like that, you have to wonder how you can not own Disney, especially when you know that CEO Bob Iger is in there buying any shares on weakness.

After that is Intel, up 22% since Dow 16,000. Ouch. Lots of people think they have missed Intel because it has gone from the mid-$20s to $30 and change. Is that really a huge distance to traverse, though? Is that such a black eye to have sat out when this stock did nothing for years and years? Forget that it was at $75 15 years ago. Just think that here's a company with a near-3% yield, a fabulous balance sheet and that sells at a discount to the average stock that has just reported much-better-than-expected earnings and has indicated that there is more to come. Plus, it has new leadership in Brian Krzanich, who is done spending money for money's sake and is demanding a much higher return on investment. What's not to like, especially now that PC demand is strengthening? That's right, strengthening. That means gross margins will keep going higher and that's the holy grail of a higher Intel stock price. 

The fourth-biggest gainer since Dow 16,000? Merck, up 20%. At one time Merck was the world's most revered drug company with the best franchises in heart drugs, cholesterol and vaccines, among a host of other areas. It then fell on hard times and many thought it has lost its way, which is why it sells at a discount to the average stock in the S&P.

But Merck's woken up. It recently sold its consumer products division to Bayer for $14 billion, a business that a year ago in "Get Rich Carefully" I predicted could be worth as much as $10 billion and was scoffed at by many. It's got a considerable animal health division that could be a terrific standalone venture or could be acquired by Zoetis (ZTS), the Pfizer (PFE) animal health spinoff, at a price that's not nearly factored into the current stock price. I love that business. There's much less government scrutiny and much higher profits.

With that cash it could continue to buy back shares or it could raise the dividend. Or, perhaps, it could make an acquisition and change its tax status through a so-called inversion. This is a Merck that wants to make money for its shareholders and CEO Ken Frazier seems to have what it takes to shake up that staid and tired culture.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

Markets

Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Our Tweets

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs